BioCentury
ARTICLE | Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

June 2, 2017 5:15 PM UTC

Regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.) signed two outcomes-based drug pricing contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN).

The insurer signed a three-year contract for AZ’s Brilinta ticagrelor, which is marketed in the U.S. to reduce the rate of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. Harvard Pilgrim will measure the reduction in hospitalizations for repeat acute coronary events for Brilinta patients compared to patients on Plavix clopidogrel. The reversible purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) is approved in the EU as Brilique...